RxDoctor Payments Data

Elaine Moen, MD

Interventional Cardiology · Indianapolis, INNPI 1649248006

Payments from drug & device makers

$4,428in general payments, 2019–2025

Across 45 payments — averaging $98.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$1K
  • Boston Scientific$971
  • Shockwave Medical, Inc$660
  • Abiomed$453
  • Philips North America LLC$364
  • Edwards Lifesciences$348
  • plus $512 from 7 others

What the payments were for

  • Food & beverage$4,428100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,428 in reported general payments places this provider in the 35th percentile of 170 interventional cardiology providers in Indiana.

See all interventional cardiology providers in Indiana

Medicare billing

Part B allowed, 2024
$85,342
Medicare patients
377
Services billed
921

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban233$275,371
EntrestoSacubitril/Valsartan49$73,096
XareltoRivaroxaban44$41,842
Repatha SureclickEvolocumab27$34,443
MultaqDronedarone Hcl17$33,234
JardianceEmpagliflozin26$31,539
BrilintaTicagrelor12$10,596
Metoprolol Succinate295$4,094
Atorvastatin Calcium288$2,473
Ranolazine ErRanolazine14$2,123
ClopidogrelClopidogrel Bisulfate173$1,920
Diltiazem 24hr Er (Cd)Diltiazem Hcl45$1,676
Potassium Chloride67$1,646
Ezetimibe81$1,543
Carvedilol188$1,441

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$18$73,09649 claims
Johnson & JohnsonXarelto$23$41,84244 claims
AstraZenecaBrilinta$24$10,59612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 170 interventional cardiology providers in Indiana.

Other interventional cardiology in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →